Author
Perry Boy Chandra Siahaan(1
), Firman Firdauz(2), Mardi Fadillah(3),
(1) Universitas Teuku Umar, Fakultas Kesehatan Masyarakat Program Studi Kesehatan Masyarakat, Indonesia
(2) Universitas Teuku Umar, Fakultas Kesehatan Masyarakat Program Studi Kesehatan Masyarakat,
(3) Universitas Teuku Umar, Fakultas Kesehatan Masyarakat Program Studi Kesehatan Masyarakat,
Corresponding Author
| Article Analytic |
Available online: 2025-02-20 | Published : 2025-02-20
Copyright (c) 2025 Perry Boy Chandra Siahaan, Firman Firdauz, Mardi Fadillah
Article can trace at:
Article Metrics
Abstract Views: 72 times
PDF Downloaded: 50 times
Abstract
Tuberculosis is an infectious disease caused by bacteria from the Mycobacterium group, namely Mycobacterium tuberculosis, which attacks the lungs. WHO recommends the use of Molecular Rapid Tests as an initial examination for the diagnosis of Tuberculosis in patients with Pulmonary TB. Molecular Rapid Test examination is a molecular examination with Nucleic Acid Amplification Technology (NAAT) technology that can diagnose TB and resistance to Rifampicin in less than 2 hours. This study aims to determine the diagnostic test of molecular rapid tests in detecting M. tuberculosis bacteria in TB patients at H. Adam Malik Hospital Medan. This research was conducted at the Microbiology Laboratory of H. Adam Malik Hospital Medan in June - August 2024, starting from literature search to writing research reports. The population in this study were all sputum patients with suspected pulmonary tuberculosis at H. Adam Malik Hospital Medan. The sampling technique is Total Sampling where the number of samples is equal to the number of pupulations, namely 108 patients in 2024. The results of the Molecular Rapid Test research obtained 105 people had positive results found Mycobacterium tuberculosis bacteria. Based on the percentage of the results of the Molecular Rapid Test, 105 people had positive results found Mycobacterium tuberculosis bacteria and 3 people had no Mycobacterium tuberculosis bacteria found. From these data, it can be seen that the sensitivity value of the Molecular Rapid Test tool is 97,2%. The conclusion of this study is that the molecular rapid test in detecting Mycobacterium tuberculosis bacteria can be used as a screening to diagnose TB disease.
Keywords
References
Accumedia. (2010 : Rev 05). Lowentein - Jensen medium (7245). PI 7245. Diakses pada 20 Februari 2021, dari www.neogen.com/Acumedia/pdf/ProdInfo/7245_PI_pdf.
Albert, H., Bwanga, F., & Mukkada, S. (2010). Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda. BMC Infectious Disease, 10(41).
Badan Litbang Kesehatan. (2013). Riskesdas Dalam Angka Tahun 2013. Jakarta: Badan Litbang Kesehatan, Kementerian Kesehatan RI.
Blakemore, R., Story, E., Helb, D., & Kop, J. (2011). Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol, 48(7):2495-2501.
Bodmer, T., Strhle, A. (2012). Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test. J. Vis. Exp. (62), e3547 10.3791/3547, DOI :10.3791/3547 (2012)
Boehme. (2011). Study protocol-Xpert TM MTB/RIF demonstration-feasibility, impact and cost-efficiency of decentralizing molecular testing for detection of tuberculosis and rifampicin rsistance using XperTM MTB/RIF. FIND, N Eng J Med, 1005-1015.
Boulware, D. R. (2013). Utility of the Xpert MTB/RIF assay for diagnosis of tuberculosis meningitis. PLoS Med, 10(10).
Calligaro, G. L., Moodley, L., Symons, G., & Dheda, K. (2014). The medical and surgical treatment of drug resistant tuberculosis. J Thorac Dis, 6(3):186-195.
Caminero. (2013). Justification for the guidelines. Dalam: Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis. International Union Against Tuberculosis and Lung Disease, 1-6.
Chiang, C. Y. (2013). Basic concepts and definitions of drug resistance in tuberculosis Dalam Guidelines for Clinical and Operational Management of DrugResistant Tuberculosis. International Union Against Tuberculosis and Lung Disease, 13-25.
Da Silva, P. E. A., & Palomino, J. C. (2011). Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. Antimicrob Chemother, 66:14171430.
Dinas Kesehatan Provinsi Sumatera Utara. (2020). Provinsi Sumatera Utara Dalam Angka. Medan
Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. (2013). Petunjuk teknis manajemen terpadu pengendalian tuberkulosis resistan obat. Kementerian Kesehatan Republik Indonesia. 1-86.
Enarson, D. A., Harries, A.D. (2013). Historical background and global epidemiology of Mycobacterium tuberculosis resistance. Dalam: Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis. International Union Against Tuberculosis and Lung Disease, 7-12.
Evans, C. A. (2011). GeneXpert-a game-changer for tuberculosis control?. PLoS Med, 8(7).
Hakeem, A., Hussain, M. S., & Imran, M. I. (2013). GeneXpert MTB/RIF- a novel diagnostic tool for tuberculosis in pulmonary samples. IOSR Journal of Dental and Medical Sciences, 8:1-3.
Halilu, T. B., Bala, Z., Florence, S., & Yerima, I. B. (2014). Multi-drug resistance tuberculosis (mdr-tb) survey in North East Nigeria. J. Pharm. Cosmet.Sci, 2(1):15.
Haris, S. (2014). Hubungan Antara Riwayat Kontak, Kelembaban, Pencahayaan, Dan Kepadatan Hunian Dengan Kejadian Tuberkulosis Paru Pada Anak Di Kabupaten Sukoharjo. FKM Universitas Muhammadiyah Surakarta.
Hanafi, A. R., & Prasenohadi. (2010). Mekanisme dan diagnosis multidrug resistant tuberculosis. Diakses pada 20 Februari 2021, dari www.ppti.info/2010/07/mekanisme-dan-diagnosis-multidrug.html.
Infodatin. (2018). Tuberkulosis.
Kemenkes RI. (2017). Petunjuk Teknis Pemeriksaan TB Menggunakan Tes Cepat Molekuler. Jakarta.
Kemenkes RI. (2018). Pengendalian Penyakit. Profil Kesehatan Indonesia Tahun 2017, Jakarta.
Kemenkes RI. (2019). Pengendalian Penyakit. Profil Kesehatan Indonesia Tahun 2018, Jakarta.
Lawn, S. D., & Nicol, M. P. (2011). Xpert MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol, 6(9):1067-82.
Liang, L., Wu, Q., & Gao, L. (2012). Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. Thorax, 67.
Li, J., Xin, J., Zhang, L., Jiang, L., Cao, H., Li, L. (2012). Rapid detection of rpoB mutations in rifampin resistant M. tuberculosis from sputum samples by denaturing gradient gel electrophoresis.Int J Med Sci;9(2):14856.
Low, S., Ang, L. W., & Cutter, J. (2011). Mortality among tuberculosis patients on treatment in Singapore. Int J Tuberc Lung Dis, 13:328-334.
Marlowe, E. M., Novan-Weekley, S. M., & Cumpio, J. (2011). Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J. Clin. Microbiol, 49(4):1621.
Menzies, D., Benedetti, A., & Paydar, A. (2011). Standardized treatment of active tuberculosis in patients with previous treatment and/or with monoresistance to isoniazid: a systematic review and metaanalysis. PLoS Med, 6(9).
Micheletti, V. C. D., Moreira, J. S., Ribeiro, M. O., Kritski, A. L., & Braga, J. U. (2014). Drug-resistant tuberculosis in subjects included in the second national survey on antituberculosis drug resistance in Porto Alegre, Brazil. J Bras Pneumol, 40(2):155-163.
Migliori, G. B., DArcy, R. M., Sotgiu, G., & Lange, C. (2011). Multidrug-resistant and extensively drug resistant tuberculosis in the West. Europe and United States: epidemiology, surveillance, and control. Clin Chest Med, 30:637-665.
Minh, N. N., Van Bac, N., & Son, N. T. (2012). Molecular characteristics of rifampin-and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Vietnam. J Clin Microbiol, 50(3).
Minion, J., Gallant, V., & Wolfe, J. (2013). Multidrug and extensively drug-resistant tuberculosis in Canada 19972008: demographic and disease characteristics. PLoS One, 8.
Ministry of Health and Family Welfare. (2011). Revised national TB control programme training manual for Mycobacterium tuberculosis culture & drug susceptibility test. New Delhi, 5-19.
Notoatmodjo, S. (2012). Metodologi Penelitian Kesehatan. Jakarta: Rineka Cipta.
Nwokoye, N. N., Onubogu, C. C., & Nwadike, O. P. (2014). Non-conforming rifampicin susceptibility test reports from Xpert MTB/RIF assay: the national reference laboratory experience in Nigeria. Open Science Journal of Clinical Medicine, 2(2):59-62.
Patel, D. M., Patel, S. D., Jaiswal, P., & Brahmbhatt, K. J. (2012). Drug resistant Mycobacterium tuberculosis and new drug development. Int. J. Drug Dev. & Res, 4(2):76-91.
Pinto, L., & Menzies, D. (2011). Treatment of drug-resistant tuberculosis. Infection and Drug Resistance. J Bras Pneumol, 4:129-135.
Pires, G. M., Folgosa. E., Nquobile, N., Gitta, S., & Cadir, N. (2014). Mycobacterium tuberculosis resistance to antituberculosis drugs in Mozambique. J Bras Pneumol, 40(2):142-147.
Raizada, N., Sachdeva, K. S., & Chauhan, D. S. (2014). A multi-site validation in India of the Line Probe Assay for the rapid diagnosis of multi-drug resistant tuberculosis directly from sputum specimens. PLoS One, 9(2).
Rivani, E., Sabrina, T., Patricia, V. (2019) Perbandingan uji diagnostik GeneXpert MTB/Rif untuk mendeteksi resistensi rifampisin Mycobacterium tuberculosis pada pasien Tb paru di RSUP dr. Moh. Hoesin Palembang, JKK, 6(1).
Sjahrurachma, A. (2011). Diagnosis multi drug resistant Mycobacterium tuberculosis. Jurnal Tuberkulosis Indonesia, 7:8-10.
Small, P. M., & Pai, M. (2011). Tuberculosis diagnosis-time for a game change. N Engl J Med, 1070-1071.
Soepandi, P. Z. (2011). Diagnosis dan faktor yang mempengaruhi terjadinya MDR TB. Jurnal Tuberkulosis Indonesia, 6(10):16-9.
Steingart, K. R., Sohn, H., & Schiller, L. (2013). Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults (review). Cochrane Database of Systematic Reviews, 1:1-35.
Susanti, E, Amir, Z, Siagian, P, Yunita, R, Eyanoer PC. (2015). Uji Diagnostik GeneXpert MTB/Rif Di Rumah Sakit Umum Pusat Haji Adam Malik Medan, Jurnal Biosains, 1(2).
Susilawati TN, Saptawati L, Damayanti KE, Larasati R. (2018). Evaluasi Metode GeneXpert MTB/Rif dengan Sampel Raw Sputum untuk Mendeteksi Tuberkulosis Paru, Jurnal Epidemiologi Kesehatan Indonesia, 2(1).
Trbucq, A., Enarson, D. A., & Chiang, C. Y. (2011). Xpert MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?. Int J Tuberc Lung Dis, 15(12):15671571.
Van Rie, A., Page-Shipp, L., Scott, L., Sanne, I., & Stevens, W. (2010). Xpert MTB/RIF for point-of care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope?. Expert Rev Mol Diagn, 10(7):937-946.
Widyanto, F. C., & Triwibowo, C. (2013). Trend Disease. Jakarta: CV. Trans Info Media.
World Health Organization. (2011). Automatic real-time nucleic acid amplification technology for rapid and simultaneous detection and rifampicin resistance: Xpert MTB/RIF system. Diakses pada 20 Februari 2021, dari www.who.int/tb/challenges/mdr/tdrfaqs/en/.
World Health Organization. (2011). Rapid implementation of the Xpert MTB/RIF diagnostic test. Diakses pada 20 Februrari 2021, dari www.who.int/tb/challenges/mdr/tdrfaqs/en/.
World Health Organization. (2012). Drug-resistant tuberculosis. Diakses pada 20 Februari 2021, dari www.who.int/tb/challenges/mdr/tdrfaqs/en/.
World Health Organization. (2013). Global tuberculosis report 2013. Diakses pada 20 Februari 2021, dari www.who.int/tb/challenges/mdr/tdrfaqs/en/.
World Health Organization. (2013). Defenition and reporting framework for tuberculosis-2013 revision. Diakses pada 20 Februari 2021, dari www.who.int/tb/challenges/mdr/tdrfaqs/en/.
World Health Organization. (2013). The use of molecular line probe assay for detection of resistance to second-line anti-tuberculosis drug. Expert Group Meeting Report. Diakses pada 20 Februari 2021, dari www.who.int/tb/challenges/mdr/tdrfaqs/en/.
World Health Organization. (2013). Tuberculosis diagnostics Xpert MTB/RIF test. Diakses pada 20 Februari 2021, www.who.int/tb/features_archive/factsheet_xpert.pdf.
World Health Organization. (2014). Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational How-to, practical consideration. Dilihat pada 20 Februari 2021, www.who.int/tb/challenges/mdr/tdrfaqs/en/.
World Health Organization. (2020). Global tuberculosis report 2020. Diakses pada 08 Juli 2021, dari https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2020
Yadav, R. N., Singh, B. K., & Sharma, S. K. (2013). Comparative evaluation of GenoType MTBDR plus line probe assay with solid culture method in early diagnosis of multidrug resistant tuberculosis (MDR-TB) at a tertiary care centre in India. PLoS One, 8.
Yao, C., Zhu, T., & Li, Y. (2010). Detection of rpoB, katG and inhA mutations in Mycobacterium tuberculosis in clinical isolates from Chonqing as determined by microarray. Clin Microbiol Infect, 16:1639-1643.
Zhang, Y., & Yew, W. W. (2011). Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuber Lung Dis, 13(11):13201330.
Zhao, Y., Xu, S., & Wang, L. (2012). National survey of drug resistant tuberculosis in China. N Engl J Med, 366:2161-2170.
Zumla, A. I., Raviglione, M., Hafner, R., & Von, R. C. F. (2013). Tuberculosis. N. Engl J. Med, 368:745-75
Zuraida. (2021). Studi Literatur Hasil Pemeriksaan Tcm (Tes Cepat Molekuler), Mikroskopik Bta Dan Kultur Pada Suspek TB (Tuberkulosis). Jurnal Ilmiah Analis Kesehatan, 7 (1).
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
